Cited 0 times in
Prognostic value of alpha-fetoprotein in patients who achieve a complete response to transarterial chemoembolization for hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, JS | - |
dc.contributor.author | Chon, YE | - |
dc.contributor.author | Kim, BK | - |
dc.contributor.author | Park, JY | - |
dc.contributor.author | Kim, DY | - |
dc.contributor.author | Ahn, SH | - |
dc.contributor.author | Han, KH | - |
dc.contributor.author | Kang, W | - |
dc.contributor.author | Choi, MS | - |
dc.contributor.author | Gwak, GY | - |
dc.contributor.author | Paik, YH | - |
dc.contributor.author | Lee, JH | - |
dc.contributor.author | Koh, KC | - |
dc.contributor.author | Paik, SW | - |
dc.contributor.author | Kim, HY | - |
dc.contributor.author | Kim, TH | - |
dc.contributor.author | Yoo, K | - |
dc.contributor.author | Ha, Y | - |
dc.contributor.author | Kim, MN | - |
dc.contributor.author | Lee, JH | - |
dc.contributor.author | Hwang, SG | - |
dc.contributor.author | Kim, SS | - |
dc.contributor.author | Cho, HJ | - |
dc.contributor.author | Cheong, JY | - |
dc.contributor.author | Cho, SW | - |
dc.contributor.author | Park, SH | - |
dc.contributor.author | Heo, NY | - |
dc.contributor.author | Hong, YM | - |
dc.contributor.author | Yoon, KT | - |
dc.contributor.author | Cho, M | - |
dc.contributor.author | Park, JG | - |
dc.contributor.author | Kang, MK | - |
dc.contributor.author | Park, SY | - |
dc.contributor.author | Kweon, YO | - |
dc.contributor.author | Tak, WY | - |
dc.contributor.author | Jang, SY | - |
dc.contributor.author | Sinn, DH | - |
dc.contributor.author | Kim, SU | - |
dc.contributor.author | Korean TACE Study Group | - |
dc.date.accessioned | 2023-01-05T03:03:18Z | - |
dc.date.available | 2023-01-05T03:03:18Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/23658 | - |
dc.description.abstract | Purpose: Alpha-fetoprotein (AFP) is a prognostic marker for hepatocellular carcinoma (HCC). We investigated the prognostic value of AFP levels in patients who achieved complete response (CR) to transarterial chemoembolization (TACE) for HCC. Materials and Methods: Between 2005 and 2018, 890 patients with HCC who achieved a CR to TACE were recruited. An AFP re-sponder was defined as a patient who showed elevated levels of AFP (>10 ng/mL) during TACE, but showed normalization or a >50% reduction in AFP levels after achieving a CR. Results: Among the recruited patients, 569 (63.9%) with naïve HCC and 321 (36.1%) with recurrent HCC after complete resection were treated. Before TACE, 305 (34.3%) patients had multiple tumors, 219 (24.6%) had a maximal tumor size >3 cm, and 22 (2.5%) had portal vein tumor thrombosis. The median AFP level after achieving a CR was 6.36 ng/mL. After a CR, 473 (53.1%) patients experienced recurrence, and 417 (46.9%) died [median progression-free survival (PFS) and overall survival (OS) of 16.3 and 62.8 months, respectively]. High AFP levels at CR (>20 ng/mL) were independently associated with a shorter PFS [hazard ratio (HR)=1.403] and OS (HR=1.284), together with tumor multiplicity at TACE (HR=1.518 and 1.666, respectively). AFP non-respond-ers at CR (76.2%, n=359 of 471) showed a shorter PFS (median 10.5 months vs. 15.5 months, HR=1.375) and OS (median 41.4 months vs. 61.8 months, HR=1.424) than AFP responders (all p=0.001). Conclusion: High AFP levels and AFP non-responders were independently associated with poor outcomes after TACE. AFP holds clinical implications for detailed risk stratification upon achieving a CR after TACE. | - |
dc.format | application/pdf | - |
dc.language.iso | en | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | alpha-Fetoproteins | - |
dc.subject.MESH | Arteries | - |
dc.subject.MESH | Carcinoma, Hepatocellular | - |
dc.subject.MESH | Chemoembolization, Therapeutic | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Venous Thrombosis | - |
dc.title | Prognostic value of alpha-fetoprotein in patients who achieve a complete response to transarterial chemoembolization for hepatocellular carcinoma | - |
dc.type | Article | - |
dc.identifier.pmid | 33381930 | - |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820452/ | - |
dc.subject.keyword | Alpha-fetoprotein | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | Transarterial chemoembolization | - |
dc.subject.keyword | Treatment outcome | - |
dc.subject.keyword | carcinoma, hepatocellular | - |
dc.contributor.affiliatedAuthor | 김, 순선 | - |
dc.contributor.affiliatedAuthor | 조, 효정 | - |
dc.contributor.affiliatedAuthor | 정, 재연 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.3349/ymj.2021.62.1.12 | - |
dc.citation.title | Yonsei medical journal | - |
dc.citation.volume | 62 | - |
dc.citation.number | 1 | - |
dc.citation.date | 2021 | - |
dc.citation.startPage | 12 | - |
dc.citation.endPage | 20 | - |
dc.identifier.bibliographicCitation | Yonsei medical journal, 62(1). : 12-20, 2021 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.relation.journalid | J005135796 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.